Aspire Biopharma closes second tranche of $21M preferred offering; funds Dura Driver acquisition

Aspire Biopharma Holdings, Inc.

Closed second tranche of Series A Convertible Preferred stock on April 15, 2026 for 12,500 shares and gross proceeds of ~$10M.
Combined with first tranche (13,750 shares, $11M), total offering raises $21M before fees.
Amended Certificate of Designation to increase authorized Series A shares from 25,000 to 30,000.
Net proceeds to fund cash portion of proposed Dura Driver Control Systems acquisition and for general corporate purposes.
RBW Capital Partners acting through Dawson James Securities acted as placement agent.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Aspire Biopharma Holdings, Inc.: On April 13, 2026, the Company filed a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, amending provisions including the designation and number of shares, designating 30,000 shares with a par value of $0.0001 and a stated value of $1,000 per share (effective 2026-04-13).

Change: charter amendment
Effective: 2026-04-13

Exact text from the filing

On April 13, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock (the “ Certificate of Amendment ”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-017145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.